JPMorgan initiated coverage of Opko Health (OPK) with a Neutral rating and no price target Following a series of asset sales and monetizing transactions, Opko is closing in on its goal of becoming a self-funded biotech company, the analyst tells investors in a research note. However, the firm believes it will take a series of clinical wins to gain broader investor recognition, with shares likely to trade range-bound over the mid-term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPK:
- Opko, Mullen, Appian, Cintas, Apollo: Insider Moves Unveiled
- OPKO Health’s Strategic Buyback and Innovative Partnership Drive Yi Chen’s Buy Rating
- Iron Mountain, EOG, Oklo, NuScale, Opko: Insider Moves Unveiled
- Opko Health board authorizes $100M increase to existing share repurchase program
- Opko Health management to meet with Piper Sandler